title: T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.
abstract: Intensive chemotherapy with tyrosine kinase inhibitor (TKI) improves the prognosis of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). However, the prognosis of cases of relapsed or refractory Ph-ALL remains poor. Here, we aimed to assess the efficacy of T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation (TCR-haplo-HSCT) in eight patients with relapsed or refractory pediatric Ph-ALL. Transplant-related mortality was observed in two patients. All patients discontinued TKI after receiving TCR-haplo-HSCT. The 3-year probability of overall survival and event-free survival was 75.0 and 62.5%, respectively. These results indicate the efficacy of TCR-haplo-HSCT for relapsed/refractory pediatric Ph-ALL.
authors: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
authors: Hideki
authors: H
authors: Sano
authors: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
authors: Kazuhiro
authors: K
authors: Mochizuki
authors: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
authors: Mitsuko
authors: M
authors: Akaihata
authors: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
authors: Shogo
authors: S
authors: Kobayashi
authors: Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
authors: Hitoshi
authors: H
authors: Ohto
authors: Department of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
authors: Atsushi
authors: A
authors: Kikuta
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000628:therapy*; D010677:Philadelphia Chromosome; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D016879:Salvage Therapy; D013601:T-Lymphocytes / Q000276:immunology*; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: Philadelphia chromosome; acute lymphoblastic leukemia; children; haploidentical hematopoietic stem cell transplantation; relapse; tyrosine kinase inhibitor